enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Study reveals how cannabis triggers psychosis - AOL

   www.aol.com/news/study-reveals-cannabis-triggers...

   Cannabis is a known risk factor for developing psychosis that can progress to schizophrenia but this is the first time researchers have found brain-level changes in an at-risk population in real time.

3. FDA approves new type of schizophrenia drug - AOL

   www.aol.com/news/fda-approves-type-schizophrenia...

   The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...

4. FDA Approves the First New Schizophrenia Drug in Decades - AOL

   www.aol.com/fda-approves-first-schizophrenia...

   N o new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...

5. Brilaroxazine - Wikipedia

   en.wikipedia.org/wiki/Brilaroxazine

   RECOVER-2 is a confirmatory 4-week, randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of 450 acute schizophrenia patients, where patients will receive brilaroxazine 30 mg, 50 mg, or placebo once daily. Completion is expected in Q2 2025 and brilaroxazine FDA new drug application (NDA) submission is expected in Q3 ...

6. Alkermes plc - Wikipedia

   en.wikipedia.org/wiki/Alkermes_plc

   Alkermes has four proprietary commercial drug products [5] approved for the treatment of schizophrenia, bipolar I disorder, alcohol dependence and opioid dependence.These include olanzapine and samidorphan (Lybalvi), an atypical antipsychotic and opioid modulator combination intended for the treatment of schizophrenia and bipolar I disorder; aripiprazole lauroxil (Aristada), a long-acting ...

7. Roluperidone - Wikipedia

   en.wikipedia.org/wiki/Roluperidone

   Roluperidone (former developmental code names MIN-101, CYR-101, MT-210) is a 5-HT 2A and σ 2 receptor antagonist under development by Minerva Neurosciences for the treatment of schizophrenia.